

Available online at www.sciencedirect.com



Tetrahedron Letters 45 (2004) 1773-1775

Tetrahedron Letters

Concise and stereocontrolled syntheses of phosphonate *C*-glycoside analogues of β -D-ManNAc and β -D-GlcNAc 1-*O*-phosphates $\stackrel{\text{tr}}{\Rightarrow}$

Xianghui Wen and Philip G. Hultin*

Department of Chemistry, The University of Manitoba, Winnipeg, MB, Canada R3T 2N2

Received 3 November 2003; revised 10 December 2003; accepted 12 December 2003

Abstract—Diethyl C-(2-deoxy-2-acetamido- β -D-mannopyranosyl)methylphosphonate and dimethyl C-(2-deoxy-2-acetamido- β -D-glucopyranosyl)methylphosphonate were stereoselectively prepared from N-acetyl D-glucosamine. Routes to such compounds starting from D-GlcNAc have been problematic, but we have found short and efficient implementations of this highly desirable transformation.

© 2003 Elsevier Ltd. All rights reserved.

C-Glycosyl analogues of sugar 1-O-phosphates have recently attracted attention due to their potential as glycosyltransferase inhibitors.¹ Convenient routes to C-glycosyl analogues of N-acetyl D-mannosamine 1-Ophosphate and N-acetyl D-glucosamine 1-O-phosphate are particularly desirable² because carbohydrate phosphates are key intermediates in the assembly of oligo- and polysaccharides in bacteria and higher organisms.

Although many routes to *C*-glycosides exist, few are applicable to the preparation of 2-deoxy-2-acetamido β -*C*-glycosides.³⁻⁸ Even less has been reported on the preparation of 2-deoxy-2-acetamido *C*-glycosylphosphonates. In fact, the difficulties associated with the 2-acetamido group have induced most researchers to employ other hexose or pentose starting materials, and to install the acetamido group after the key C–C bond forming reaction. Such approaches have typically entailed many steps and low overall yields.^{2a-c}

Given the availability and low cost of *N*-acetyl-D-glucosamine, we were convinced that expeditious routes directly from this inexpensive material could be devised, and this has proven to be the case. Here we report the syntheses of analogues 1 and 2, of *N*-acetyl β -D-mannosamine- and *N*-acetyl β -D-glucosamine 1-*O*-phosphates.⁹ We have found particularly concise and attractive routes, beginning from well-known, simple, and readily-made derivatives of D-GlcNAc.



The synthesis of D-mannosyl analogue 1 started from *N*-acetyl glucosamine derivative 3^{10} (Scheme 1). Treatment of compound 3 with (EtO)₂P(O)CHLiP(O)(OEt)₂ in the presence of ZnBr₂ gave α,β -unsaturated phosphonate 4 in good yield. In the absence of ZnBr₂, a compound identified by NMR as 8^{11} was obtained instead, presumably from retro-aldol reaction of 3 followed by a Wittig reaction. This was caused by the stronger basicity of the lithium diphosphonate compared to the zinc diphosphonate. Similar retro-aldol/Wittig products have been observed when reducing sugars were treated with nonstabilized ylides.¹²

Compound 4 underwent Michael cyclization upon treatment with $K_2CO_3/EtOH$, to give the β -C-mannopyranosyl product 7. We noted that 5 was formed first, and could in fact be recovered in impure form from incomplete reactions. Intermediate 5 disappeared over time with concurrent formation of 7, presumably via the

Keywords: GlcNAc phosphate; ManNAc phosphate; Amino *C*-glycosides; Amino *C*-glycosylphosphonates.

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2003.12.081

^{*} Corresponding author. Tel.: +1-204-474-9814; fax: +204-474-7608; e-mail: hultin@cc.umanitoba.ca



Scheme 1. Reagents and conditions: (i) BuLi, ZnBr₂ (3 equiv), (EtO)₂P(O)CH₂P(O)(OEt)₂ (6 equiv), THF, -78 °C to rt, 2 h, 85%; (ii) K₂CO₃, EtOH, overnight; (iii) 80% HOAc, 80 °C, 1 h, 60% over the last two steps.

intermediate 6. We were unable to detect 6. More strongly basic conditions (KOt-Bu/THF, EtONa/EtOH, or NaOH/EtOH) gave low yields of the desired product. Acid hydrolysis of the benzylidene protecting group in 7 furnished the D-manno analogue 1^{13} in 60% yield from 4.

The origin of the *manno*-stereoselectivity in the transformation of **4** to **7** is unclear. There is literature precedent for the formation of both cyclic and acyclic ManNAc products from the olefination of GlcNAc derivatives.¹⁴ However, calculations and equilibration studies by Davis and co-workers^{14b} confirm that β -Glc-NAc-*C*-pyranosides are the thermodynamically favored ring forms. We attempted to rationalize the apparent preference for **6** over **4** using molecular mechanics, but the results of these preliminary calculations were not illuminating.

Our initial approach to the synthesis of D-gluco analogue 2 began with the known alcohol 9^{2e} (Scheme 2). Swern oxidation of 9 afforded two aldehydes in a 5:1 ratio (as judged by TLC and NMR). The addition of (EtO)₂POLi to the crude aldehydes gave hydroxy phosphonate 10a in 66% yield, along with 13% of an isomeric product that appeared by NMR to be 10b (both were single diastercomers at C-1, but the stereochemistry at this center was not identified). C-Glycosidic aldehydes may be epimerized under the basic conditions of the Swern oxidation, favoring an equatorial orientation.¹⁵ Arbuzov-type addition to this isomer would



Scheme 2. Reagents and conditions: (i) Oxalyl chloride, DMSO, Et₃N, CH₂Cl₂, -78 °C to rt, 30 min; (ii) HOP(OEt)₂, BuLi, THF, -78 °C to rt, 2.5 h, 66% of 10a+13% of 10b; (iii) CS₂, NaH, MeI, THF, rt, overnight; (iv) Bu₃SnH, AIBN, toluene, 80 °C, 20 min, 46% over the last two steps.

afford 10a. We have not optimized the oxidation of 9, but we note the possibility that either 10a or 10b might be obtained by optimal choice of reaction conditions.

Deoxygenation of compound 10 also turned out to be problematic. Attempted reduction using Zn/HOAc, NaBH₄/TFA, or SmI₂/Ac₂O/THF failed to produce any significant amount of 11. Attempts to convert 10a to an olefin by treatment of its mesylate derivative with DBN were also unsuccessful. Finally, 10a was converted to the xanthate, which was reduced by Bu₃SnH to give the desired product 11 in 46% yield from 10a.

The strategy shown in Scheme 2 suffered from the low yield of the deoxygenation step, as well as the fact that starting compound **9** required several steps to prepare from *N*-acetyl glucosamine.^{2e} Therefore, we decided to pursue a more efficient synthetic route.

Our preferred route to 2 is shown in Scheme 3. The synthesis started from lactone 12,¹⁶ available from D-GlcNAc in three simple steps. Addition of (MeO)₂POCH₂Li to 12 generated β -hydroxy phosphonate 13 in excellent yield. Direct reductive deoxygenation of compound 13 also proved to be difficult. Attempted reductions with Et₃SiH/BF₃·Et₂O, Et₃SiH/TFA, Et₃SiH/TMSOTf, Ph₃SiH/Et₂AlCl, and NaBH₄/TFA did not afford 2. However, when compound 13 was treated with Ac₂O/NaOAc at 100 °C, olefin 14¹⁷ could be obtained in good yield. Other elimination conditions (oxalyl chlo-



Scheme 3. Reagents and conditions: (i) $(MeO)_2POCH_2Li$, THF, -78 °C, 96%; (ii) Ac₂O, AcONa, 100 °C, 70%; (iii) H₂ (g), Pd/C, HOAc, quant.

ride/pyridine, SOCl₂/pyridine, POCl₃/pyridine) only afforded complex mixtures. Hydrogenation of olefin 14 quantitatively furnished the product 2. Efficient methods for the conversion of *C*-glycosylphosphonate diesters similar to 1 and 2 to the corresponding phosphonate monoesters or phosphonic acids have been reported.¹⁸

We have established completely stereoselective and highly efficient routes to the β *C*-glycosyl analogues of *N*-acetyl mannosamine 1-*O*-phosphate and *N*-acetyl glucosamine 1-*O*-phosphate, starting from well-known and readily prepared derivatives of the inexpensive D-GlcNAc. These are not only useful as structural components of potential glycosyltransferase inhibitors, but they may also serve as precursors to more elaborate 2-amino β -*C*-glycosides via Horner–Emmons reaction of the phosphonate groups.

Supplementary data. Experimental procedures and spectroscopic data for compounds 1, 2, 4, 10a, 11, 13, and 14. The supplementary data are available online with the paper in ScienceDirect.

Acknowledgements

This work was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC). We also thank Dr. Kirk Marat for his assistance in obtaining NMR spectra.

References and notes

- (a) Compain, P.; Martin, O. R. *Bioorg. Med. Chem.* 2001, 9, 3077–3092; (b) El Ashry, E. S. H.; Rashed, N.; Shobier, A. H. S. *Pharmazie* 2000, 55, 251–262.
- (a) Cipolla, L.; Lay, L.; Nicotra, F.; Panza, L.; Russo, G. J. Chem. Soc., Chem. Commun. 1995, 1993–1994; (b) Casero, F.; Cipolla, L.; Lay, L.; Nicotra, F.; Panza, L.; Russo, G. J. Org. Chem. 1996, 61, 3428–3432; (c) Cipolla, L.; Lay, L.; Nicotra, F. J. Org. Chem. 1997, 62, 6678– 6681; (d) Gaurat, O.; Xie, J.; Valery, J.-M. Tetrahedron Lett. 2000, 41, 1187–1189; z(e) Schafer, A.; Thiem, J. J. Org. Chem. 2000, 65, 24–29; (f) Grugier, J.; Xie, J.; Duarte, I.; Valery, J.-M. J. Org. Chem. 2000, 65, 979–984.
- (a) Roe, B. A.; Boojamra, C. G.; Griggs, J. L.; Bertozzi, C. R. J. Org. Chem. 1996, 61, 6442–6445; (b) Cui, J.; Horton, D. Carbohydr. Res. 1998, 309, 319–330.
- (a) Burhart, F.; Hoffmann, M.; Kessler, H. Angew. Chem., Int. Ed. 1997, 36, 1191–1192; (b) Hoffmann, M.; Burkhart, F.; Hessler, G.; Kessler, H. Helv. Chim. Acta 1996, 79, 1519–1532; (c) Burkhart, F.; Kessler, H. Tetrahedron Lett. 1998, 39, 255–256.
- 5. Fuchss, T.; Schmidt, R. R. Synthesis 1998, 753-758.
- Pachamuthu, K.; Gupta, A.; Das, J.; Schmidt, R. R.; Vankar, Y. D. *Eur. J. Org. Chem.* **2002**, 1479–1483.
- Yang, G.; Franck, R. W.; Bittman, R.; Samadder, P.; Arthur, G. Org. Lett. 2001, 3, 197–200.

- Xie, J.; Molina, A.; Czernecki, S. J. Carbohydr. Chem. 1999, 18, 481–498.
- 9. For the α *C*-glycosyl analogues of *N*-acetyl mannosamine and *N*-acetyl glucosamine 1-*O*-phosphates, see Ref. 2b.
- 10. Holmquist, L. Acta Chem. Scand. 1970, 24, 173-178.
- 11. Compound 8 was obtained under a variety of reaction conditions. It was identified as diethyl (3S,4R)-3,5-Obenzylidene-4-hydroxy-(*E*)-1-pentene-1-phosphonate from the following data, supported by DEPT, COSY, HSQC, and NOE experiments: $[\alpha]_D$ –54.5° (*c* 1.05, CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃): δ 1.33 (dt, 6H, J = 0.8 and 7.1), 3.62 (dddd, 1H, J = 10.1, 4.1, 5.0, and 8.8, H-4), 3.68 (dd, 1H, J = 10.1 and 10.1, H-5), 4.00–4.14 (m, 4H), 4.23 (dd, 1H, J = 8.8, 3.2, and 2.0, H-3), 4.32 (dd, 1H, J = 10.1 and 4.1, H-5), 5.44 (d, 1H, J = 5.0, OH), 5.58 (s, 1H), 6.11 (ddd, 1H, J = 21.6, 17.2, and 2.0, H-1), 7.26 (ddd, 1H, $J = 3.2, 17.2, \text{ and } 23.3, \text{ H-2}), 7.34-7.57 \text{ (m, 5H);} {}^{13}\text{C}$ NMR (75.5 MHz, CDCl₃) δ 16.64 (d, J = 6.5), 62.44 (d, J = 5.6), 62.46 (d, J = 5.5), 65.36 (d, J = 1.9), 72.00 (s), 81.36 (d, J = 20.5), 101.10 (s), 116.36 (d, J = 188.9), 149.99 (d, J = 6.7); ³¹P NMR (121.5 MHz, CDCl₃): δ 20.41; ESI-MS (m/z): 343.34.
- 12. Giannis, A.; Munster, P.; Sandhoff, K.; Steglich, W. *Tetrahedron* **1988**, *44*, 7177–7180.
- 13. Compound 1 was obtained as a glassy solid. Its configuration was confirmed by NOE correlations between $H_{NH}-H_{4'}$, $H_1-H_{4'}$, $H_{1'}-H_{2'}$, and $H_{1'}-H_{3'}$.



- (a) Giannis, A.; Henk, T.; Sandhoff, K. EP 0385287 A2, 5 September 1990 (b) Werner, R. M.; Williams, L. M.; Davis, J. T. *Tetrahedron Lett.* **1998**, *39*, 9135–9138.
- 15. Petrusova, M.; BeMiller, J. N.; Krihova, A.; Petrus, L. *Carbohydr. Res.* **1996**, *295*, 57–67.
- (a) Pravdić, N.; Fletcher, H. G., Jr.; *Carbohydr. Res.* 1971, 19, 353–364; (b) Molina, A.; Czernecki, S.; Xie, J. *Tetrahedron Lett.* 1998, 39, 7507–7510.
- 17. Compound 14 was obtained as white needles. Only one isomer of 14 was observed. An NOE experiment showed correlations between H_1 -NH, H_1 - $H_{2'}$, and H_1 - $H_{3'}$.



 (a) Borodkin, V. S.; Milne, F. C.; Ferguson, M. A. J.; Nikolaev, A. V. *Tetrahedron Lett.* **2002**, *43*, 7821–7825; (b) Vidil, C.; Morere, A.; Garcia, M.; Barragan, V.; Hamdaoui, B.; Rochefort, H.; Montero, J.-L. *Eur. J. Org. Chem.* **1999**, 447–450; (c) Cipolla, L.; La Ferla, B.; Nicotra, F.; Panza, L. *Tetrahedron Lett.* **1997**, *38*, 5567–5568.